SMT202000222T1 - Adenovirus oncolitico che codifica per una proteina b7 - Google Patents

Adenovirus oncolitico che codifica per una proteina b7

Info

Publication number
SMT202000222T1
SMT202000222T1 SM20200222T SMT202000222T SMT202000222T1 SM T202000222 T1 SMT202000222 T1 SM T202000222T1 SM 20200222 T SM20200222 T SM 20200222T SM T202000222 T SMT202000222 T SM T202000222T SM T202000222 T1 SMT202000222 T1 SM T202000222T1
Authority
SM
San Marino
Prior art keywords
protein
oncolytic adenovirus
adenovirus encoding
encoding
oncolytic
Prior art date
Application number
SM20200222T
Other languages
English (en)
Italian (it)
Inventor
Brian Robert Champion
Alice Claire Noel Bromley
Original Assignee
Psioxus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1507419.8A external-priority patent/GB201507419D0/en
Priority claimed from GBGB1516936.0A external-priority patent/GB201516936D0/en
Priority claimed from GBGB1522013.0A external-priority patent/GB201522013D0/en
Application filed by Psioxus Therapeutics Ltd filed Critical Psioxus Therapeutics Ltd
Publication of SMT202000222T1 publication Critical patent/SMT202000222T1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SM20200222T 2015-04-30 2016-04-29 Adenovirus oncolitico che codifica per una proteina b7 SMT202000222T1 (it)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1507419.8A GB201507419D0 (en) 2015-04-30 2015-04-30 Virus
GBGB1516936.0A GB201516936D0 (en) 2015-09-24 2015-09-24 Virus
GBGB1522013.0A GB201522013D0 (en) 2015-12-14 2015-12-14 Virus
EP16723043.2A EP3288573B1 (en) 2015-04-30 2016-04-29 Oncolytic adenovirus encoding a b7 protein
PCT/EP2016/059609 WO2016174200A1 (en) 2015-04-30 2016-04-29 Oncolytic adenovirus encoding a b7 protein

Publications (1)

Publication Number Publication Date
SMT202000222T1 true SMT202000222T1 (it) 2020-05-08

Family

ID=56008588

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20200222T SMT202000222T1 (it) 2015-04-30 2016-04-29 Adenovirus oncolitico che codifica per una proteina b7

Country Status (31)

Country Link
US (6) US11000559B2 (https=)
EP (2) EP3391892A1 (https=)
JP (3) JP6931229B2 (https=)
KR (4) KR102854512B1 (https=)
CN (2) CN107690479B (https=)
AU (3) AU2016256582B2 (https=)
BR (2) BR112017023171A2 (https=)
CA (1) CA2984038C (https=)
CL (2) CL2017002731A1 (https=)
CO (1) CO2017010831A2 (https=)
CY (1) CY1122833T1 (https=)
DK (1) DK3288573T3 (https=)
EA (1) EA037611B1 (https=)
ES (1) ES2780366T3 (https=)
HR (1) HRP20200439T1 (https=)
HU (1) HUE048320T2 (https=)
IL (3) IL284375B (https=)
LT (1) LT3288573T (https=)
MX (1) MX2017013684A (https=)
MY (1) MY183703A (https=)
PE (2) PE20181140A1 (https=)
PH (1) PH12017501942A1 (https=)
PL (1) PL3288573T3 (https=)
PT (1) PT3288573T (https=)
RS (1) RS60105B1 (https=)
SA (2) SA520412637B1 (https=)
SG (3) SG10201803081TA (https=)
SI (1) SI3288573T1 (https=)
SM (1) SMT202000222T1 (https=)
WO (1) WO2016174200A1 (https=)
ZA (1) ZA201801589B (https=)

Families Citing this family (40)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
CA2914790C (en) 2013-06-14 2024-02-27 Psioxus Therapeutics Limited A dosing regime and formulations for type b adenoviruses
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
HUE035875T2 (hu) 2013-10-25 2018-06-28 Psioxus Therapeutics Ltd HeterolĆ³g gĆ©neket tartalmazĆ³ onkolitikus adenovĆ­rusok
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
HRP20200439T1 (hr) 2015-04-30 2020-06-12 Psioxus Therapeutics Limited Onkolitički adenovirus koji kodira protein b7
US10273281B2 (en) 2015-11-02 2019-04-30 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
BR112018012180A2 (pt) * 2015-12-17 2018-12-04 Psioxus Therapeutics Ltd vĆ­rus de codificaĆ§Ć£o de um anticorpo ou fragmento de complexo anti-tcr
JP7466271B2 (ja) * 2016-03-31 2024-04-12 悶 ćƒØćƒ¼ćƒ­ćƒ”ć‚¢ćƒ³ ćƒ¢ćƒ¬ć‚­ćƒ„ćƒ©ćƒ¼ 惐悤ć‚Ŗ惭ć‚øćƒ¼ ćƒ©ćƒœćƒ©ćƒˆćƒŖćƒ¼ ć‚¢ćƒ‡ćƒŽć‚¦ć‚¤ćƒ«ć‚¹ć‚³ćƒ¼ćƒˆć‚æćƒ³ćƒ‘ć‚Æč³Ŗē”±ę„é€é”č³¦å½¢å‰¤
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
IL303187A (en) 2016-08-29 2023-07-01 Akamis Bio Ltd Adenovirus with bispecific T cell activator
ES2981703T3 (es) 2016-09-02 2024-10-10 Lentigen Tech Inc Composiciones y mƩtodos para tratar cƔncer con DuoCars
JP7138946B2 (ja) * 2016-09-27 2022-09-20 悻悤ć‚æćƒ¼ ć‚»ćƒ©ćƒ”ćƒ„ćƒ¼ćƒ†ć‚£ć‚Æć‚¹ ć‚Ø惫ć‚Øćƒ«ć‚·ćƒ¼ ęœ€é©åŒ–ć•ć‚ŒćŸč…«ē˜ęŗ¶č§£ę€§ć‚¦ć‚¤ćƒ«ć‚¹ćŠć‚ˆć³ćć®ä½æē”Ø
WO2018083257A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083258A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083259A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
JP7724601B2 (ja) * 2017-02-03 2025-08-18 ćƒ¦ćƒ‹ćƒćƒ¼ć‚·ćƒ†ć‚£ ć‚Ŗ惖 ćƒ”ćƒƒćƒ„ćƒćƒ¼ć‚° ļ¼ć‚Ŗ惖 悶 ć‚³ćƒ¢ćƒ³ć‚¦ć‚§ćƒ«ć‚¹ ć‚·ć‚¹ćƒ†ćƒ  ć‚Ŗ惖 ćƒć‚¤ćƒ¤ćƒ¼ ć‚Øćƒ‡ćƒ„ć‚±ć‚¤ć‚·ćƒ§ćƒ³ č…«ē˜ęŗ¶č§£ę€§ć‚¦ć‚¤ćƒ«ć‚¹ē™‚ę³•
KR20190139216A (ko) 2017-04-28 2019-12-17 ķŒŒģ“ėøŒ ķ”„ė¼ģž„ ķ…Œė¼ķ“Øķ‹±ģŠ¤, ģøķ¬. Cd80 ģ„øķ¬ģ™ø ė„ė©”ģø ķ“ė¦¬ķŽ©ķ‹°ė“œė„¼ ģ“ģš©ķ•œ ģ¹˜ė£Œ ė°©ė²•
EP3630144A4 (en) * 2017-05-25 2021-03-31 University of Central Florida Research Foundation, Inc. NEW ONCOLYTIC VIRUSES TO SENSITIZE TUMOR CELLS TO DESTRUCTION BY NATURAL KILLER CELLS
JP7216668B2 (ja) 2017-05-26 2023-02-01 ć‚Øćƒ”ć‚»ćƒ³ćƒˆć‚¢ćƒ¼ćƒ«ć‚Ø惃ć‚Æć‚¹ļ¼Œć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ å°Žå…„éŗä¼å­ć‚’äæęŒć™ć‚‹ēµ„ę›ćˆć‚¢ćƒ‡ćƒŽć‚¦ć‚¤ćƒ«ć‚¹
DK3630143T5 (da) 2017-06-01 2024-09-02 Akamis Bio Ltd Onkolytisk virus og fremgangsmƄde
WO2019147921A1 (en) * 2018-01-26 2019-08-01 Nantcell, Inc. Rapid verification of virus particle production for a personalized vaccine
GB201801614D0 (en) * 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
WO2019173334A1 (en) * 2018-03-05 2019-09-12 The Schepens Eye Research Institute, Inc. Engineered vegf variants for retinal neuroprotection, promotion of axon growth and axon regeneration
KR20200136972A (ko) * 2018-03-30 2020-12-08 ė„ėŖØķ‚¤ ė„ė„ ģ¢…ģ°½ ė°œģƒ ģ–µģ œķ˜• ģ¢…ģ–‘ ģš©ķ•“ģ„± ė°”ģ“ėŸ¬ģŠ¤
WO2020052551A1 (en) * 2018-09-10 2020-03-19 Genesail Biotech (Shanghai) Co. Ltd. A modified oncolytic virus, composition and use thereof
US12589132B2 (en) 2019-02-22 2026-03-31 Five Prime Therapeutics, Inc. CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors
EA202192420A1 (ru) * 2019-03-05 2021-12-13 Š­Š¼Š“Š¶ŠµŠ½ Š˜Š½Šŗ. ŠŸŃ€ŠøŠ¼ŠµŠ½ŠµŠ½ŠøŠµ Š¾Š½ŠŗŠ¾Š»ŠøтŠøчŠµŃŠŗŠøх Š²ŠøрусŠ¾Š² Š“Š»Ń Š»ŠµŃ‡ŠµŠ½Šøя рŠ°ŠŗŠ°
EP3725323A1 (en) * 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada
US20220249127A1 (en) * 2019-05-14 2022-08-11 Oncolys Biopharma Inc. Method for administering oncolytic virus to tumor tissue, and device for administration
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
GB201909081D0 (en) 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
GB202102049D0 (en) 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses
JP2024520444A (ja) 2021-05-24 2024-05-24 ćƒ—ćƒ­ćƒ“ć‚§ćƒ³ć‚·ćƒ§ćƒ³ćƒ»ćƒć‚¤ć‚Ŗćƒ»ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ļ¼‘åž‹ē³–å°æē—…ć‚’ę²»ē™‚ć™ć‚‹ćŸć‚ć®ę–¹ę³•
WO2022252185A1 (zh) * 2021-06-03 2022-12-08 äøŠęµ·å…č‹±ē”Ÿē‰©åŒ»čÆē§‘ęŠ€ęœ‰é™å…¬åø ęŗ¶ē˜¤ē—…ęÆ’č½½ä½“åŠå…¶åŗ”ē”Ø
CA3233100A1 (en) 2021-09-23 2023-03-30 Sagittarius Bio, Inc. Adenoviruses and methods for using adenoviruses
EP4499846A1 (en) * 2022-03-25 2025-02-05 UniversitƤt ZĆ¼rich Adenoviral mediated targeting of activated immune cells
AU2024277678A1 (en) 2023-05-25 2025-11-27 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses

Family Cites Families (75)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thƩrapie gƩnique.
SK282843B6 (sk) 1993-07-13 2002-12-03 Rhone-Poulenc Rorer S. A. DefektnĆ½ rekombinantnĆ½ adenovĆ­rus a farmaceutickĆ½ prostriedok s jeho obsahom
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
US5877011A (en) 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
CN1242051A (zh) 1996-12-31 2000-01-19 ę˜‚å°¼å…‹ę–ÆčÆē‰©å…¬åø ē”ØäŗŽč‚æē˜¤ę²»ē–—和预防ēš„臓ē»†čƒžē—…变ē—…ęƒ
EP1036183B1 (en) 1997-02-20 2007-10-03 The Johns Hopkins University School Of Medicine Mutations in atp-dependent transposition proteins that reduce target-site specificity
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
US20020019051A1 (en) 1998-05-27 2002-02-14 Monika Lusky Chimeric adenoviral vectors
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
CN1110553C (zh) 1998-07-15 2003-06-04 ę­å·žčµ›ē‹®ē”Ÿē‰©ęŠ€ęœÆå¼€å‘ęœ‰é™å…¬åø åŸŗå› å·„ē؋č…ŗē—…ęƒ及其ē”Ø途
US6455314B1 (en) 1998-09-11 2002-09-24 Genvec, Inc. Alternatively targeted adenovirus
DK1137792T3 (da) 1998-12-09 2007-09-10 Us Gov Health & Human Serv En rekombinant vektor, der udtrykker adskillige costimulatoriske molekyler, og anvendelser deraf
ES2372823T3 (es) 1999-05-17 2012-01-26 Crucell Holland B.V. Adenovirus recombinante del serotipo ad11.
EP1181382B1 (en) 1999-06-01 2005-03-23 The University of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
US7396679B2 (en) 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
GB2375113B (en) 2000-01-21 2004-10-20 Biovex Ltd A modified, oncolytic, non-laboratory HSV strain and its use in treating cancer
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
WO2001092549A2 (en) 2000-05-31 2001-12-06 Genvec, Inc. Method and composition for targeting an adenoviral vector
ATE449859T1 (de) 2001-01-04 2009-12-15 Goeran Wadell Virusvektor zur gentherapie
US20050175589A1 (en) 2001-07-13 2005-08-11 Btg International Limited Anti-neoplastic viral agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1327688A1 (en) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
CA2474777A1 (en) 2002-02-01 2003-08-07 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with pods
US20060147420A1 (en) 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
US7858367B2 (en) 2002-04-30 2010-12-28 Duke University Viral vectors and methods for producing and using the same
CN1705740B (zh) * 2002-10-15 2013-07-24 佩尔Ā·ę¾å†…Ā·éœå°”姆 å…·ęœ‰åå‘åŸŗ因č”Øč¾¾ēš„č…ŗē—…ęƒ及其åŗ”ē”Ø
US20040167088A1 (en) 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo
WO2004087930A1 (en) 2003-03-28 2004-10-14 Saint Louis University Adenovirus replication-competent vectors expressing trail
US20050136035A1 (en) 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
US20050036989A1 (en) 2003-07-18 2005-02-17 Onyx Pharmaceuticals, Inc. Subgroup B adenoviral vectors for treating disease
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
US20080292592A1 (en) 2004-04-30 2008-11-27 Sunil Chada Oncolytic Adenovirus Armed with Therapeutic Genes
BRPI0510475B8 (pt) * 2004-05-26 2021-05-25 Bayer Pharma AG adenovĆ­rus quimĆ©rico recombinante, uso do mesmo no tratamento de cĆ¢ncer e mĆ©todos de inibiĆ§Ć£o de crescimento de uma cĆ©lula de cĆ¢ncer, de fornecimento de uma proteĆ­na terapĆŖutica a uma cĆ©lula e para o isolamento do adenovĆ­rus
CN100361710C (zh) 2004-06-07 2008-01-16 ęˆéƒ½åŗ·å¼˜ē”Ÿē‰©ē§‘ęŠ€ęœ‰é™å…¬åø č‚æē˜¤ē»†čƒžäø“äø€č”Øč¾¾å…ē–«č°ƒčŠ‚因子gm-csfēš„ęŗ¶ē˜¤ę€§č…ŗē—…ęƒ重ē»„体ēš„ęž„å»ŗ及其åŗ”ē”Ø
US20060292682A1 (en) * 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
CN101068933A (zh) * 2004-08-25 2007-11-07 ē»†čƒžåŸŗ因ē³»ē»Ÿęœ‰é™å…¬åø ē”ØäŗŽč‚æē˜¤ē»†čƒžå¢žå¼ŗč½¬åƼēš„ēŗ¤ē»“äæ®é„°ēš„č…ŗē—…ęÆ’č½½ä½“
EP1784493A2 (en) * 2004-09-01 2007-05-16 The Government of the United States of America as Represented by The Department of Health and Human Services Adenoviral vectors able to transduce apcs, potential use in immune response generation
US20090208924A1 (en) 2004-12-01 2009-08-20 Bayer Schering Pharma Aktiengesellschaft Generation of Replication Competent Viruses for Therapeutic Use
BRPI0615400A2 (pt) 2005-08-31 2011-05-17 Genvec Inc vacinas para malƔria baseadas em vetor adenoviral
DE102005055128B4 (de) 2005-11-15 2015-04-02 UniversitƤt Rostock Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
ES2304281B1 (es) 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
WO2008080003A2 (en) 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Generation of oncolytic adenoviruses and uses thereof
EP2296678A4 (en) 2008-05-27 2012-03-21 Oncolytics Biotech Inc MODULATION OF INTERSTITIAL PRESSURE AND ONCOLYTIC VIRUS RELIEF AND DISTRIBUTION
CN101381742A (zh) * 2008-10-23 2009-03-11 ęµ™ę±Ÿē†å·„大学 ꙚꜟåÆåŠØå­é¶å‘ę€§č°ƒęŽ§ęŗ¶ē˜¤č…ŗē—…ęƒpCN305č½½ä½“åŠå…¶ęž„å»ŗę–¹ę³•äøŽåŗ”ē”Ø
ES2385251B1 (es) 2009-05-06 2013-05-06 FundaciĆ³ Privada Institut D'investigaciĆ³ BiomĆØdica De Bellvitge Adenovirus oncolĆ­ticos para el tratamiento del cĆ”ncer.
WO2011043719A1 (en) * 2009-10-05 2011-04-14 Ya-Fang Mei Replicating viral vectors for gene therapy
CN103237889B (zh) 2010-08-16 2017-04-05 čØ克ē”Ÿē‰©ē ”ē©¶å­¦é™¢ č…ŗē—…ęƒē»„č£…ę–¹ę³•
US20130323205A1 (en) * 2010-09-24 2013-12-05 Oncos Therapeutics Oy Oncolytic adenoviral vectors and methods and uses related thereto
US20130243731A1 (en) 2010-09-24 2013-09-19 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti-ctla-4 antibodies
JP2015507604A (ja) 2011-11-14 2015-03-12 ćƒŖć‚øć‚§ćƒćƒ¬ć‚¤ćƒ†ć‚£ćƒ– 悵悤ć‚Øćƒ³ć‚·ćƒ¼ć‚ŗļ¼Œ ć‚Ø惫ć‚Øćƒ«ć‚·ćƒ¼ ę‡øęæē²’å­é€é”ć‚·ć‚¹ćƒ†ćƒ ćŠć‚ˆć³ę–¹ę³•
CN102586327B (zh) 2012-01-18 2013-09-11 陕č„æåøˆčŒƒå¤§å­¦ äø€ę­„ę³•ęž„å»ŗęŗåø¦å¤–ęŗåŸŗ因ēš„d24ēŗ¤ē»“蛋ē™½äæ®é„°ēš„ę”件复制型č…ŗē—…ęÆ’č½½ä½“åŠå…¶åŗ”ē”Ø
WO2014138314A1 (en) 2013-03-05 2014-09-12 Baylor College Of Medicine Oncolytic virus
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
HUE035875T2 (hu) * 2013-10-25 2018-06-28 Psioxus Therapeutics Ltd HeterolĆ³g gĆ©neket tartalmazĆ³ onkolitikus adenovĆ­rusok
CN106029889A (zh) 2013-11-22 2016-10-12 德那ēæ äøęœ‰é™å…¬åø č”Øč¾¾å…ē–«ē»†čƒžåˆŗęæ€å—体ęæ€åŠØ剂ēš„č…ŗē—…ęƒ
GB201406608D0 (en) * 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
GB201510197D0 (en) * 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
GB201503500D0 (en) 2015-03-02 2015-04-15 Ucl Business Plc Cell
AU2016232009B2 (en) 2015-03-17 2021-07-15 Tilt Biotherapeutics Oy Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto
HRP20200439T1 (hr) 2015-04-30 2020-06-12 Psioxus Therapeutics Limited Onkolitički adenovirus koji kodira protein b7
BR112018012180A2 (pt) 2015-12-17 2018-12-04 Psioxus Therapeutics Ltd vĆ­rus de codificaĆ§Ć£o de um anticorpo ou fragmento de complexo anti-tcr
CN109312364A (zh) 2016-03-18 2019-02-05 ę²³č°·ē»†čƒžęœ‰é™å…¬åø ē”ØäŗŽę„ŸęŸ“ę ‘ēŖēŠ¶ē»†čƒžēš„多ęØ”å¼č½½ä½“
IL303187A (en) 2016-08-29 2023-07-01 Akamis Bio Ltd Adenovirus with bispecific T cell activator
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
WO2018075978A1 (en) 2016-10-20 2018-04-26 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083259A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
DK3630143T5 (da) * 2017-06-01 2024-09-02 Akamis Bio Ltd Onkolytisk virus og fremgangsmƄde
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation

Also Published As

Publication number Publication date
US20210338753A1 (en) 2021-11-04
CN107690479A (zh) 2018-02-13
PE20181140A1 (es) 2018-07-17
US10322152B2 (en) 2019-06-18
CA2984038C (en) 2023-01-03
MX2017013684A (es) 2018-08-28
SG10201803081TA (en) 2018-06-28
SA520412637B1 (ar) 2022-03-01
PT3288573T (pt) 2020-03-25
EA201791971A1 (ru) 2018-04-30
KR20180022638A (ko) 2018-03-06
SG10201901482XA (en) 2019-03-28
SA517390260B1 (ar) 2021-11-10
IL255286B (en) 2021-01-31
HRP20200439T1 (hr) 2020-06-12
JP7162929B2 (ja) 2022-10-31
US10124028B2 (en) 2018-11-13
JP6928380B2 (ja) 2021-09-01
IL284375B (en) 2022-07-01
AU2020223665A1 (en) 2020-09-10
KR102643574B1 (ko) 2024-03-06
KR20240032177A (ko) 2024-03-08
BR112017023171A2 (pt) 2018-07-17
US11000559B2 (en) 2021-05-11
LT3288573T (lt) 2020-03-25
BR122018004815A2 (pt) 2019-09-10
PL3288573T3 (pl) 2020-05-18
WO2016174200A1 (en) 2016-11-03
AU2016256582A1 (en) 2017-11-16
MY183703A (en) 2021-03-09
CN108396015A (zh) 2018-08-14
CN108396015B (zh) 2022-02-18
CA2984038A1 (en) 2016-11-03
US20180042973A1 (en) 2018-02-15
JP6931229B2 (ja) 2021-09-01
HUE048320T2 (hu) 2020-07-28
HK1249009A1 (en) 2018-10-26
US20190076493A1 (en) 2019-03-14
KR102854512B1 (ko) 2025-09-04
AU2018201446B2 (en) 2020-05-28
EP3391892A1 (en) 2018-10-24
AU2016256582B2 (en) 2020-10-29
AU2018201446A1 (en) 2018-03-29
CO2017010831A2 (es) 2018-02-28
CY1122833T1 (el) 2021-05-05
EA037611B1 (ru) 2021-04-21
DK3288573T3 (da) 2020-03-16
JP2018139586A (ja) 2018-09-13
SG11201708604TA (en) 2017-11-29
JP2021176339A (ja) 2021-11-11
EP3288573A1 (en) 2018-03-07
IL258044B (en) 2021-07-29
IL258044A (en) 2018-05-31
ES2780366T3 (es) 2020-08-25
IL255286A0 (en) 2017-12-31
SI3288573T1 (sl) 2020-06-30
US10548929B2 (en) 2020-02-04
CL2018000587A1 (es) 2018-08-10
JP2018514199A (ja) 2018-06-07
AU2016256582A8 (en) 2018-01-18
CN107690479B (zh) 2022-02-18
RS60105B1 (sr) 2020-05-29
US20180140649A1 (en) 2018-05-24
US20170266243A1 (en) 2017-09-21
PH12017501942A1 (en) 2018-03-19
IL284375A (en) 2021-07-29
KR20180118249A (ko) 2018-10-30
US20170056458A1 (en) 2017-03-02
CL2017002731A1 (es) 2018-06-08
PE20180241A1 (es) 2018-01-31
KR20250134212A (ko) 2025-09-09
US10849945B2 (en) 2020-12-01
ZA201801589B (en) 2019-10-30
EP3288573B1 (en) 2020-02-12

Similar Documents

Publication Publication Date Title
IL258044A (en) Oncolytic adenovirus encoding the b7 protein
IL260027A (en) A group b adenovirus that encodes an anti-tcr-complex antibody or particle
ZA201802261B (en) Polypeptides
PL3659614T3 (pl) Onkolityczny wirus krowianki
IL254577A0 (en) polypeptides
GB201713765D0 (en) Modified adenovirus
GB201409634D0 (en) Intra block copy mode encoding choice
PL3303290T3 (pl) Modulatory ROR-gamma
PL3303291T3 (pl) Modulatory ROR-gamma
PL3303293T3 (pl) Modulatory ROR-gamma
SG11201706882VA (en) Polypeptides
ZA201704366B (en) Il-17a-binding polypeptides
PL3319942T3 (pl) MODULATORY ROR-GAMMA (RORĪ³)
GB201417535D0 (en) Adapting encoding properties
IL267267A (en) Vibration sensing system with wavelength encoding
GB201401877D0 (en) Peptides
EP3239962A4 (en) Encoding device
GB2539417B (en) Optimized multi-view image encoding
GB201520655D0 (en) Multi-mode sensor
GB201614607D0 (en) Modified adenovirus
GB201706219D0 (en) Modified adenovirus
GB201700663D0 (en) Modified adenovirus
GB201401159D0 (en) Adenovirus
GB201516655D0 (en) IX sensor
GB201502178D0 (en) Detecting polypeptides